Company Analysis
Sign in

Denali Therapeutics Inc. (DNLI)

Nasdaq: DNLI · Biological Products, (No Diagnostic Substances) · South San Francisco, CA · filing with the SEC since 2017
Full chart Alerts Compare
Grade5.7
◀ Past 5.7● Present 7.3▶ Future 4.1
4 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

52 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Denali Therapeutics Inc.’s names, not what it holds today.

Patents granted
52
52 utility, 1976 to Dec 31, 2025
Granted in 2025
5
Against 10 in 2024 and 12 in 2023
Applications published
121
17 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Organic fine chemistry18
Pharmaceuticals12
Biotechnology6
Analysis of biological materials2
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
DENALI THERAPEUTICS INC. its own name
US, as the owner printed on each patent
52 granted
82 published
Denali Therapeutics Inc. its own name
named as the applicant on its applications, in US
0 granted
39 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Dec 16, 202512,497,387Process for the preparation of pyrimidinyl-4-aminopyrazole compoundsOrganic fine chemistryDENALI THERAPEUTICS INC.
Aug 5, 202512,378,540Fusion proteins comprising acid alpha-glucosidase enzymes and methods thereofPharmaceuticalsDENALI THERAPEUTICS INC.
Jul 15, 202512,358,928Compounds, compositions and methodsPharmaceuticalsDENALI THERAPEUTICS INC.
Jul 15, 202512,358,896LRRK2 inhibitors and methods of making and using thereofPharmaceuticalsDENALI THERAPEUTICS INC.
Mar 4, 202512,240,902Anti-TREM2 antibodies and methods of use thereofPharmaceuticalsDENALI THERAPEUTICS INC.
Dec 31, 202412,180,211Compounds, compositions and methodsPharmaceuticalsDENALI THERAPEUTICS INC.
Dec 10, 202412,162,948Methods of engineering transferrin receptor binding polypeptidesBiotechnologyDENALI THERAPEUTICS INC.
Nov 12, 202412,139,478Compounds, compositions and methodsOrganic fine chemistryDENALI THERAPEUTICS INC.
Oct 29, 202412,129,263Kinase inhibitors and uses thereofOrganic fine chemistryDENALI THERAPEUTICS INC.
Sep 17, 202412,091,392Compounds, compositions and methodsOrganic fine chemistryDENALI THERAPEUTICS INC.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 25, 20252025/0388601Compounds, Compositions and MethodsOrganic fine chemistryDENALI THERAPEUTICS INC.
Dec 25, 20252025/0388595MODULATORS OF EUKARYOTIC INITIATION FACTOR 2B, COMPOSITIONS AND METHODSOrganic fine chemistryDenali Therapeutics Inc.
Dec 25, 20252025/0387477ANTI-TRANSFERRIN RECEPTOR FUSION PROTEINS AND METHODS OF USE THEREOFPharmaceuticalsDENALI THERAPEUTICS INC.
Dec 11, 20252025/0376432PROCESS FOR PREPARING MODULATORS OF EUKARYOTIC INITIATION FACTOR 2BOrganic fine chemistryDenali Therapeutics Inc.
Dec 4, 20252025/0372225A QUANTITATIVE PHARMACOLOGICAL MODEL OF ENZYME REPLACEMENT THERAPYMedical technologyDenali Therapeutics Inc.
Dec 4, 20252025/0367284ANTI-TRANSFERRIN RECEPTOR FUSION PROTEINS AND METHODS OF USE THEREOFPharmaceuticalsDENALI THERAPEUTICS INC.
Oct 30, 20252025/0333528TRANSFERRIN RECEPTOR-BINDING DOMAINS AND PROTEINS COMPRISING THE SAMEBiotechnologyDenali Therapeutics Inc.
Sep 25, 20252025/0297023METHODS OF ENGINEERING TRANSFERRIN RECEPTOR BINDING POLYPEPTIDESBiotechnologyDENALI THERAPEUTICS INC.
Aug 7, 20252025/0250555FUSION PROTEINS COMPRISING ACID ALPHA-GLUCOSIDASE ENZYMES AND METHODS THEREOFPharmaceuticalsDENALI THERAPEUTICS INC. · patent 12,378,540 granted from it
Jul 3, 20252025/0215077MONOVALENT ANTI-TREM2 BINDING MOLECULES AND METHODS OF USE THEREOFBiotechnologyDENALI THERAPEUTICS INC.
What it applied for, 2024 to 2025: Pharmaceuticals 16 · Biotechnology 9 · Organic fine chemistry 9 · Analysis of biological materials 1 · Computer technology 1 · Medical technology 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton DNLI · research, not advice